Did the Ban on Asbestos Reduce the Incidence of Mesothelioma?

Michele Carbone; Haining Yang; Harvey I. Pass; Emanuela Taioli

doi:10.1016/j.jtho.2023.03.013

Did the Ban on Asbestos Reduce the Incidence of Mesothelioma?

Michele Carbone, Haining Yang, Harvey I. Pass, Emanuela Taioli

Research output: Contribution to journal › Editorial

13 Scopus citations

Original language	English
Pages (from-to)	694-697
Number of pages	4
Journal	Journal of Thoracic Oncology
Volume	18
Issue number	6
DOIs	https://doi.org/10.1016/j.jtho.2023.03.013
State	Published - Jun 2023

Access to Document

10.1016/j.jtho.2023.03.013

Cite this

@article{e3afe628ee8e407face57c36826e684d,

title = "Did the Ban on Asbestos Reduce the Incidence of Mesothelioma?",

author = "Michele Carbone and Haining Yang and Pass, {Harvey I.} and Emanuela Taioli",

note = "Funding Information: Disclosure: Dr. Carbone has a patent issued for “Methods for Diagnosing a Predisposition to Develop Cancer”; and is a board-certified pathologist who provides consultation for pleural pathological characteristics, including medical-legal. Drs. Carbone and Yang have a patent issued for “Using Anti-HMGB1 Monoclonal Antibody or other HMGB1 Antibodies as a Novel Mesothelioma Therapeutic Strategy” and a patent issued for “HMGB1 As a Biomarker for Asbestos Exposure and Mesothelioma Early Detection.” Drs. Carbone and Yang report receiving funding from the National Institute of Environmental Health Sciences (1R01ES030948-01 by Drs. Carbone and Yang); the National Cancer Institute (1R01CA237235-01A1 by Drs. Carbone and Yang and 1R01CA198138 by Dr. Carbone); the U.S. Department of Defense (DoD) (W81XWH-16-1-0440 by Drs. Carbone, Yang, and Pass); and from the UH Foundation through donations from: the Riviera United-4-a Cure (Drs. Carbone and Yang), the Melohn Family Endowment, the Honeywell International Inc., the Germaine Hope Brennan Foundation, and the Maurice and Joanna Sullivan Family Foundation (Dr. Carbone). Drs. Pass and Yang report receiving funding from the Early Detection Research Network (NCI 5U01CA214195-04). Dr. Pass reports receiving funding from Genentech , Belluck , and Fox LLP . Dr. Taioli reports receiving federal funding unrelated to asbestos or to mesothelioma and has consulted with law firms in litigations unrelated to asbestos or mesothelioma. ",

year = "2023",

month = jun,

doi = "10.1016/j.jtho.2023.03.013",

language = "English",

volume = "18",

pages = "694--697",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",